Knowing that ovarian cancer is a disease with very limited therapeutic options, the above preliminary data suggest that MET inhibitors compounds seem to be very promising therapeutic candidates and they deserve serious consideration for further clinical development in treating patients with ovarian cancer. This evidence concerns the gene MET and ovarian carcinoma.